Leaderboard

My Dream Paediatric Oncology AI Agent – Jenny_2030 Future Scenario: A children’s cancer centre. Jenny now supports paediatric oncology teams, young patients (ages 4–17), and their families throughout the chemotherapy process, prioritizing safety, empathy, education, and emotional resilience. Enhanced Capabilities of Jenny for Paediatric Chemotherapy: 1. Communication Jenny uses an interaction style that is based on a child’s age and emotional maturity considering different age ranges. 2. Family-Centered Care Coordination Jenny keeps parents informed with real-time updates on vitals, treatment milestones, and side-effect risks and reminder alerts for hospital visitations and drugs usage. 3. Emotional Monitoring Consideration Jenny analyses facial expressions such as tone, movement, and sleep pattern and also alerts paediatric psychologists and care teams when it detects any irregularities in the child’s emotions. 4. Safe Chemotherapy Customization Jenny continually references global paediatric oncology databases to ensure evidence-based, child-specific protocols are followed. Risk to Guard Against: Emotional Overattachment Children may develop strong attachments to Jenny as a comforting presence, which could lead to distress if Jenny is perceived as “withholding” bad news. Safeguards: Jenny is designed with psychological advisors to balance truth and empathy. She also supports difficult conversations alongside clinicians (humans), it does not replace humans.

The narrow / weak AI technology that we currently use has numerous technical limitations preventing full reliability on AI systems. Let us assume that five years from now these limitations are addressed due to evolving technology. In that case, if we could design an ideal AI agent for the BPO environment, there are few capabilities the agent would have. Ideal agent capabilities: 1. End to end process management: The agent would manage the entire process (not only routine tasks) eliminating the need for human intervention. The agent would gain cross functional knowledge through self-learning and its enhanced unstructured data handling capabilities. It would also be able to integrate across systems seamlessly without the need for API’s or other integration mechanisms. 2. Self-directed process improvement: Agents will have the ability to identify process inefficiencies / variations, underlying root causes and propose validated improvement recommendations. Eventually they incorporate those recommendations and finetune demonstrating continuous improvement capabilities. 3. Emotional intelligence: Natural language processing (NLP) could have superior emotions handling capabilities that could enable agents to listen and respond like a skilled human. It will provide emotionally tailored responses displaying happiness, empathy etc. 4. Superior Personalization: Agents shall have the ability to remember historical (over longer periods) conversations and personalize their responses proactively. 5. Seamless collaboration: Agents will be able to participate in team meetings along with humans, ask a human agent questions, listen to the conversations, summarize key takeaways and change behaviors / performance as required. There will be seamless collaboration between the human and AI agents. Probably these capabilities are currently being experimented or at a fictional stage, however this could become a reality sooner or later. Risk Guard: Under such circumstances, one of the risks that I would want to guard against would be the risk of human skill erosion. With AI taking over human responsibilities, there comes the risk of fading problem solving, critical thinking, creativity and other skills. On conflicting situations that demand these skills, human intervention must still be sought.

AI Agent for Pharma R&D Literature Search Key capabilities: 1. Raw Contextual Grasp: a. Analyzes scientific literature such as papers and clinical trials at a near-human level and derives hypotheses, methodologies, and results even when relying on incomplete or self-contradictory information. b. Point out implications without a clear or logical basis towards hypothesis suggesting (“X off-target effect by Compound X in The Cell paper is consistent with unpublished toxicity data”). 2. Hypothesis Generation: a. While integrating (cross-referencing) unrelated fields, propose new theory directions. Ex: Alzheimer’s mechanism in Nature could apply to your Parkinson’s work, here’s a synthesis pathway. b. Anticipate no innovation “white space” opportunities. For example, Cyst inhibition has never been investigated for this rare cancer subtype. 3. Real-Time Collaborative Curation: a. Act as a co-scientist alongside researchers as a thought partner who participates to dynamically update during meetings (new Preprint just dropped that challenges your target—do you want to review?). b. Create visual summaries, including but not limited to competing drug mechanisms such as interactive graphs. 4. Regulatory and Competitive Intelligence: a. Show awareness for worldwide rule setting, such as FDA’s new guidance on digital endpoints has an impact within phase III design, and how it relates to the supervision of competitor pipelines, like rival Y, has dropped this target because they showed signals of unsafe markers. 5. Oversight Self-Validating Citations: a. Citations would need evaluation based on rationale and scores given to documents where they achieved self-revalidation of the set hypothesis, indicating that they exceeded verification of their arguments. AI interaction with humans: 1. For Researchers: a. Voice/chat interface ("List me all active patents related to molecule A that have a controlled release drug profile”). b. "Pop-up" notifications for important updates ("Reference product is delisted from the US market due to potential adverse effect"). 2. For Executives: a. Generates a clear report stating risk and benefits involved with the diagram ("Here’s why launching product A aligns with the current product portfolio in the market."). Potential Risk to Guard Against: Overlooking important information: · The AI can be overdependent on "highly reviewed articles from reputed papers" or institutional biases (e.g., ignoring new research or recent findings due to low or no popularity). Risk mitigation plan: · Add special prompts that force AI to search the entire information irrespective of popularity, review, or rating. · Mandatory requirement of human signature or confirmation, especially in high-risk recommendations. (e.g., clinical trial design changes)